These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21425998)

  • 1. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.
    Mulvihill MJ; Cooke A; Rosenfeld-Franklin M; Buck E; Foreman K; Landfair D; O'Connor M; Pirritt C; Sun Y; Yao Y; Arnold LD; Gibson NW; Ji QS
    Future Med Chem; 2009 Sep; 1(6):1153-71. PubMed ID: 21425998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
    Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
    Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
    Jin M; Kleinberg A; Cooke A; Gokhale PC; Foreman K; Dong H; Siu KW; Bittner MA; Mulvihill KM; Yao Y; Landfair D; O'Connor M; Mak G; Pachter JA; Wild R; Rosenfeld-Franklin M; Ji Q; Mulvihill MJ
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1176-80. PubMed ID: 21251824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
    Jin M; Wang J; Buck E; Mulvihill MJ
    Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
    Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
    McKinley ET; Bugaj JE; Zhao P; Guleryuz S; Mantis C; Gokhale PC; Wild R; Manning HC
    Clin Cancer Res; 2011 May; 17(10):3332-40. PubMed ID: 21257723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.
    Leiphrakpam PD; Agarwal E; Mathiesen M; Haferbier KL; Brattain MG; Chowdhury S
    Oncol Rep; 2014 Jan; 31(1):87-94. PubMed ID: 24173770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
    Wittman M; Carboni J; Attar R; Balasubramanian B; Balimane P; Brassil P; Beaulieu F; Chang C; Clarke W; Dell J; Eummer J; Frennesson D; Gottardis M; Greer A; Hansel S; Hurlburt W; Jacobson B; Krishnananthan S; Lee FY; Li A; Lin TA; Liu P; Ouellet C; Sang X; Saulnier MG; Stoffan K; Sun Y; Velaparthi U; Wong H; Yang Z; Zimmermann K; Zoeckler M; Vyas D
    J Med Chem; 2005 Sep; 48(18):5639-43. PubMed ID: 16134929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, β-cell functions, and β-cell proliferation in male mice.
    Shirakawa J; Okuyama T; Yoshida E; Shimizu M; Horigome Y; Tuno T; Hayasaka M; Abe S; Fuse M; Togashi Y; Terauchi Y
    Endocrinology; 2014 Jun; 155(6):2102-11. PubMed ID: 24712877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.
    Fairhurst RA; Marsilje TH; Stutz S; Boos A; Niklaus M; Chen B; Jiang S; Lu W; Furet P; McCarthy C; Stauffer F; Guagnano V; Vaupel A; Michellys PY; Schnell C; Jeay S
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2057-64. PubMed ID: 26951753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin receptor structure and its implications for the IGF-1 receptor.
    Lawrence MC; McKern NM; Ward CW
    Curr Opin Struct Biol; 2007 Dec; 17(6):699-705. PubMed ID: 17851071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors.
    Mulvihill MJ; Ji QS; Werner D; Beck P; Cesario C; Cooke A; Cox M; Crew A; Dong H; Feng L; Foreman KW; Mak G; Nigro A; O'Connor M; Saroglou L; Stolz KM; Sujka I; Volk B; Weng Q; Wilkes R
    Bioorg Med Chem Lett; 2007 Feb; 17(4):1091-7. PubMed ID: 17127062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
    Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
    Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
    Zimmermann K; Wittman MD; Saulnier MG; Velaparthi U; Sang X; Frennesson DB; Struzynski C; Seitz SP; He L; Carboni JM; Li A; Greer AF; Gottardis M; Attar RM; Yang Z; Balimane P; Discenza LN; Lee FY; Sinz M; Kim S; Vyas D
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1744-8. PubMed ID: 20153189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
    Flanigan SA; Pitts TM; Eckhardt SG; Tentler JJ; Tan AC; Thorburn A; Leong S
    Clin Cancer Res; 2010 Nov; 16(22):5436-46. PubMed ID: 20943761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
    Steiner L; Blum G; Friedmann Y; Levitzki A
    Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.
    Bell IM; Stirdivant SM; Ahern J; Culberson JC; Darke PL; Dinsmore CJ; Drakas RA; Gallicchio SN; Graham SL; Heimbrook DC; Hall DL; Hua J; Kett NR; Kim AS; Kornienko M; Kuo LC; Munshi SK; Quigley AG; Reid JC; Trotter BW; Waxman LH; Williams TM; Zartman CB
    Biochemistry; 2005 Jul; 44(27):9430-40. PubMed ID: 15996097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solution structure of ectodomains of the insulin receptor family: the ectodomain of the type 1 insulin-like growth factor receptor displays asymmetry of ligand binding accompanied by limited conformational change.
    Whitten AE; Smith BJ; Menting JG; Margetts MB; McKern NM; Lovrecz GO; Adams TE; Richards K; Bentley JD; Trewhella J; Ward CW; Lawrence MC
    J Mol Biol; 2009 Dec; 394(5):878-92. PubMed ID: 19835884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
    Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
    Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.